Results 131 to 140 of about 179,210 (301)

BUSM News and Notes [PDF]

, 1991
Monthly newsletter providing updates of interest to the Boston University School of Medicine ...
Boston University School of Medicine Office of Informational Services
core  

Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy

BMEMat, EarlyView.
A ROS‐responsive, zwitterionic nanocage enables stable, intranasal siRNA delivery to glioblastoma, promoting deep tumor penetration via non‐degradative pathways and trigeminal nerve transport. This platform achieves durable gene silencing and tumor suppression, offering a non‐invasive, storage‐stable strategy for treating glioma and other neurological ...
Jingwen Xie, Jingxing Si, Xiaobei Deng, Jing Tan, Ruijie Zhu, Jizhou Qi, Gaoxia Ma, Bin Wang, Yi Wang, Yunzhou Guo, Yuping Chen, Shiqun Shao, Youqing Shen   +12 more
wiley   +1 more source

An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. [PDF]

, 2016
Arangua, Paul, Carroll, Peter, Cooperberg, Matthew R., Crawford, E. David, Eastham, James, Gomella, Leonard G., Hoenemeyer, John, Klein, Eric A., Leapman, Michael, Leveridge, Mike, Loeb, Stacy, Maccini, Michael, Partin, Alan W., Pettaway, Curtis A., Pinto, Peter, Rosenberg, Matt T., Shore, Neal D., Thompson, Ian M.   +17 more
core   +2 more sources

A brief review of the literature on the malignant ureteral obstruction [PDF]

, 2018
Malignant ureteral obstruction (MUO) caused by a primarily urological tumor or secondary to a late-stage malignancy can be difficult for the urologist to manage. Due to a lack of clinical data on the management of MUO, every case is particular and should
Brînză, Adrian, Lupu, Sorin, Marcu, Dragos, Maxim, Laurian, Neagu, Tiberiu P, Peride, Ileana, Socea, Bogdan, Stanescu, Ana Maria Alexandra   +7 more
core   +1 more source

PSMA‐Targeting Macrophage Membrane‐Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer

Exploration, EarlyView.
Advanced prostate cancer is highly invasive and prone to rapid metastasis, creating an urgent need for novel therapeutic strategies. We developed a PSMA‐targeting macrophage membrane‐coated nanomedicine (P‐MMCNPs@DM1). Leveraging the immune‐evasive and active‐targeting properties of macrophage membrane coating, P‐MMCNPs@DM1 effectively managed both ...
Keying Zhang, Bo Gao, Jingwei Wang, Yu Li, Chao Xu, Fa Yang, Shaojie Liu, Hongji Li, Chao Zhang, Xiangliang Meng, Zhaokun Shi, Rui Zhang, Ruili Zhang, Zhongliang Wang, Weihong Wen, Qiang Zhang, Yuankang Zou, Donghui Han, Huijie Bian, Weijun Qin   +19 more
wiley   +1 more source

Global patterns and trends in kidney cancer incidence and mortality

International Journal of Cancer, EarlyView.
What's New? Decreasing mortality from kidney cancer in developed countries contrasts with persistently high or rising mortality in less‐developed regions. Factors underlying this widening gap remain incompletely understood. Using GLOBOCAN 2022 data, the present study examined patterns in kidney cancer incidence and mortality worldwide and the relation ...
Anton Barchuk, Jerome Vignat, Kari A. O. Tikkinen, Ahmedin Jemal, Freddie Bray, Ariana Znaor   +5 more
wiley   +1 more source

BUSM News and Notes [PDF]

, 1978
Monthly newsletter providing updates of interest to the Boston University School of Medicine ...
Boston University School of Medicine Office of Informational Services
core  

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology– and European Randomized Study of Screening for Prostate Cancer–based strategies

International Journal of Cancer, EarlyView.
What's New? Although screening reduces prostate cancer mortality, concerns about overdiagnosis and unnecessary biopsies have given rise to more tailored strategies. The European Association of Urology (EAU) proposed a risk‐adapted screening strategy combining prostate‐specific antigen (PSA)‐based intervals, a risk calculator, and magnetic resonance ...
Zhenwei Yang, Luuk A. van Duuren, Monique J. Roobol, Nicole S. Erler, Dimitris Rizopoulos, Eveline A. M. Heijnsdijk   +5 more
wiley   +1 more source